IRON Form 4: CFO sells 2,000 shares at $57.50, retains 65,530

Disc Medicine, Inc. (IRON) – Form 4 insider transaction Chief Financial Officer Jean M. Franchi disclosed the sale of 2,000 common shares on 07/10/2025 at $57.50 per share, for proceeds of roughly $115 thousand.

Rhea-AI Filing Summary

Disc Medicine, Inc. (IRON) – Form 4 insider transaction

Chief Financial Officer Jean M. Franchi disclosed the sale of 2,000 common shares on 07/10/2025 at $57.50 per share, for proceeds of roughly $115 thousand. The transaction was executed under a Rule 10b5-1 trading plan adopted on 03/10/2025, indicating it was pre-scheduled rather than discretionary. After the sale, Franchi retains 65,530 shares, a decrease of about 3% of her direct holdings, maintaining a sizable equity position that continues to align her interests with shareholders. No derivative securities acquisitions or dispositions were reported in this filing.

Positive

• Transparent disposal under Rule 10b5-1 plan, reducing concerns about information-driven selling
• CFO retains 65,530 shares, preserving substantial insider alignment with shareholders

Negative

• Insider sale by a senior executive can be interpreted as a modestly negative sentiment signal
• Reduction of approximately 3% of personal holdings marginally lowers insider ownership

Insights

Securities Analyst

TL;DR: Small, pre-planned CFO sale; negligible strategic signal, limited valuation impact.

The 2,000-share disposition equals roughly 3% of the CFO’s stake and less than 0.01% of IRON’s outstanding shares. Because it was executed under a previously adopted Rule 10b5-1 plan, the action appears routine for liquidity or diversification rather than an information-based trade. The executive still holds more than 65k shares, preserving meaningful skin in the game. From a governance and sentiment standpoint, I view the filing as neutral; it neither alters the company’s fundamentals nor provides a strong bearish signal. Market reaction is likely muted.

Insider Trade Summary

Net Seller: 2,000 shares

Net Sell 1 txn

Insider Franchi Jean M.

Role Chief Financial Officer

Sold 2,000 shs ($115K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,000	$57.50	$115K

Holdings After Transaction: Common Stock — 65,530 shares (Direct)

Footnotes (1)

1. F1. The transaction reported by the Reporting Person was effected pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Disc Medicine (IRON) shares did the CFO sell?

Jean M. Franchi sold 2,000 shares of common stock.

What price did the insider shares of IRON sell for?

The shares were sold at $57.50 each.

How many IRON shares does the CFO still own after the sale?

Following the transaction, the CFO directly owns 65,530 shares.

Was the sale executed under a Rule 10b5-1 trading plan?

Yes. The filing states the sale was made under a Rule 10b5-1 plan adopted on 03/10/2025.

Did the Form 4 report any derivative security transactions for IRON?

No derivative acquisitions or dispositions were reported in this Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/14/2025 - 09:36 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Franchi Jean M.

(Last) (First) (Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/10/2025		S(1)		2,000	D	$57.5	65,530	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported by the Reporting Person was effected pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2025.

	By: /s/ Rahul Khara, as Attorney-in-Fact	07/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.